Trial Profile
A 10-day prospective, single-center, double-blind, placebo-controlled, randomized study to evaluate safety, tolerability and pharmacokinetics of 600 mg b.i.d. oral doses of LM11A-31-BHS in healthy elderly volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Nov 2021
Price :
$35
*
At a glance
- Drugs LM 11A-31 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational
- Sponsors PharmatrophiX
- 03 Nov 2021 According to a Alzheimer's Drug Discovery Foundation media release, an analysis from this trial will be presented at the 14th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD), 2021.
- 22 May 2019 Status changed from recruiting to completed.
- 28 Sep 2018 New trial record